

WEST Search History

Hide Items

Restore

Clear

Cancel

DATE: Tuesday, August 03, 2004

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L3	L2 with angiogenesis	7
<input type="checkbox"/>	L2	L1 with human	384
<input type="checkbox"/>	L1	raf	6722

END OF SEARCH HISTORY

\$%^STN;Highlighton= ***;Highlightoff=*** ;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1800EXS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 May 12 EXTEND option available in structure searching
NEWS 4 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5 May 27 New UPM (Update Code Maximum) field for more efficient patent
SDIs in CAPLUS
NEWS 6 May 27 CAPLUS super roles and document types searchable in REGISTRY
NEWS 7 Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
and WATER from CSA now available on STN(R)
NEWS 9 Jul 12 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to BABS
NEWS 10 Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction
with the 228th ACS National Meeting
NEWS 11 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
fields
NEWS 12 AUG 02 CAPLUS and CA patent records enhanced with European and Japan
Patent Office Classifications
NEWS 13 AUG 02 STN User Update to be held August 22 in conjunction with the
228th ACS National Meeting
NEWS 14 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7.01 for Windows) now available

NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS world wide web site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 19:16:48 ON 03 AUG 2004

=> fil .eliz

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 19:16:59 ON 03 AUG 2004

FILE 'SCISEARCH' ENTERED AT 19:16:59 ON 03 AUG 2004

COPYRIGHT 2004 THOMSON ISI

FILE 'LIFESCI' ENTERED AT 19:16:59 ON 03 AUG 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 19:16:59 ON 03 AUG 2004

COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOSIS' ENTERED AT 19:16:59 ON 03 AUG 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 19:16:59 ON 03 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 19:16:59 ON 03 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 19:16:59 ON 03 AUG 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'ESBIOBASE' ENTERED AT 19:16:59 ON 03 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 19:16:59 ON 03 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 19:16:59 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

=> s raf
L1 35040 RAF

=> s l1 (5a) human
10 FILES SEARCHED...
L2 1672 L1 (5A) HUMAN

=> s l2 (5a) angiogenesis
L3 0 L2 (5A) ANGIOGENESIS

=> s l2 and angiogenesis
L4 18 L2 AND ANGIOGENESIS

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5 14 DUP REM L4 (4 DUPLICATES REMOVED)

=> d 1-10

L5 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:32220 HCAPLUS
DN 140:193831
TI Role of v-raf and truncated form RAF1 in the induction of vascular
endothelial growth factor and vascularization
AU Malecki, Maciej; Seneta, Magdalena; Miloszezewska, Joanna; Trembacz, Halina;
Przybyszewska, Malgorzata; Janik, Przemyslaw
CS Department of Cell Biology, Cancer Center, M. Sklodowska-Curie Institute
of Oncology, Warsaw, Pol.
SO Oncology Reports (2004), 11(1), 161-165
CODEN: OCRPEW; ISSN: 1021-335X
PB Oncology Reports
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 14 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
DUPLICATE 1
AN 2003-19432 BIOTECHDS
TI Novel antisense oligonucleotide which is targeted to mRNA encoding
human ***raf*** and which is capable of inhibiting raf
expression, useful for treating or preventing hyperproliferative
conditions such as cancer;
with application in diagnosis, prevention and gene therapy of cancer,
ocular ***angiogenesis*** and neovascularization
AU MONIA B P
PA MONIA B P
PI US 2003032607 13 Feb 2003
AI US 2002-57550 25 Jan 2002

PRAI US 2002-57550 25 Jan 2002; US 1994-250856 31 May 1994
DT Patent
LA English
OS WPI: 2003-503332 [47]

L5 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:329429 HCAPLUS
DN 139:143642
TI Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by .alpha.v.beta.3 and .alpha.5.beta.1 integrins
AU Sudhakar, Akulapalli; Sugimoto, Hikaru; Yang, Changqing; Lively, Julie; Zeisberg, Michael; Kalluri, Raghu
CS Program in Matrix Biology, Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 02215, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2003), 100(8), 4766-4771
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:505930 HCAPLUS
DN 139:192000
TI Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli
AU Alavi, Alireza; Hood, John D.; Frausto, Ricardo; Stupack, Dwayne G.; Cheresch, David A.
CS Department of Immunology, Scripps Research Institute, La Jolla, CA, 92037, USA
SO Science (Washington, DC, United States) (2003), 301(5629), 94-96
CODEN: SCIEAS; ISSN: 0036-8075
PB American Association for the Advancement of Science
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
AN 2002:483067 HCAPLUS
DN 137:57540
TI Antisense oligonucleotide inhibition of raf gene expression for treatment of cancer
IN Monia, Brett P.
PA Isis Pharmaceuticals, Inc., USA
SO U.S., 41 pp., Cont.-in-part of U. S. 6,090,626.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6410518	B1	20020625	US 2000-506073	20000218
	US 5563255	A	19961008	US 1994-250856	19940531
	WO 9532987	A1	19951207	WO 1995-US7111	19950531
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5952229	A	19990914	US 1996-756806	19961126
	US 5981731	A	19991109	US 1997-888982	19970707
	WO 9902167	A1	19990121	WO 1998-US13961	19980706
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6090626	A	20000718	US 1998-143214	19980828
	JP 2000152797	A2	20000606	JP 2000-8654	20000118

JP 09507502 T2 19970729
 JP 3121599 B2 20010109
 US 2003032607 A1 20030213 US 2002-57550 20020125
 US 2003119769 A1 20030626 US 2002-173225 20020614
 PRAI US 1994-250856 A1 19940531
 WO 1995-US7111 A1 19950531
 US 1996-756806 A1 19961126
 US 1997-888982 A2 19970707
 WO 1998-US13961 A2 19980706
 US 1998-143214 A2 19980828
 JP 1996-501257 A3 19950531
 US 2000-506073 A1 20000218
 US 2002-57550 A2 20020125

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:256057 HCAPLUS

DN 136:274281

TI Raf proteins, cDNA sequences, agonists or antagonists and uses thereof in
 therapy and diagnosis of endothelium affected diseases

IN Hatzopoulos, Antonis; Hautmann, Martina; Herbst, Myriam; Geishauser,
 Albert; Schoch, Juergen

PA GSF-Forschungszentrum fuer Umwelt und Gesundheit G.m.b.H., Germany

SO PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002026246	A2	20020404	WO 2001-EP11282	20010928
	WO 2002026246	A3	20031002		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002023571	A5	20020408	AU 2002-23571	20010928
PRAI	EP 2000-121490	A	20000929		
	WO 2001-EP11282	W	20010928		

L5 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:535327 HCAPLUS

DN 140:12301

TI Targeted delivery of mutant Raf kinase to neovessels causes tumor
 regression

AU Hood, J. D.; Cheresch, D. A.

CS Departments of Immunology, The Scripps Research Institute, La Jolla, CA,
 92037, USA

SO Cold Spring Harbor Symposia on Quantitative Biology (2002), 67, 285-291

CODEN: CSHSAZ; ISSN: 0091-7451

PB Cold Spring Harbor Laboratory Press

DT Journal; General Review

LA English

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:235225 HCAPLUS

DN 137:345329

TI Unraveling the complexities of the Raf/MAP kinase pathway for
 pharmacological intervention

AU Herrera, Roman; Sebolt-Leopold, Judith S.

CS Dept of Cancer Molecular Sciences, Pfizer Global Research & Development,
 Ann Arbor Laboratories, Ann Arbor, MI, 48105, USA

SO Trends in Molecular Medicine (2002), 8(4, suppl.), s27-s31

CODEN: TMMRCY; ISSN: 1471-4914

PB Elsevier Science Ltd.

DT Journal; General Review

LA English

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:137041 HCAPLUS
 DN 134:188193
 TI Protein and cDNA sequences of modified ***human*** protein kinase C-
 Raf and/or H-Ras and therapeutic uses thereof for modulation of
 angiogenesis
 IN Hood, John; Eliceiri, Brian; Cheresch, David A.
 PA The Scripps Research Institute, USA
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012210	A1	20010222	WO 2000-US21842	20000811
	WO 2001012210	C2	20020912		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1210099	A1	20020605	EP 2000-955423	20000811
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003507337	T2	20030225	JP 2001-516555	20000811
	BR 2000013228	A	20030617	BR 2000-13228	20000811
	NO 2002000718	A	20020410	NO 2002-718	20020212
	ZA 2002001761	A	20030602	ZA 2002-1761	20020301
PRAI	US 1999-148924P	P	19990813		
	US 2000-215951P	P	20000705		
	WO 2000-US21842	W	20000811		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 14 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1999:311814 BIOSIS
 DN PREV199900311814
 TI 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells.
 AU D'Angelo, Gisela [Reprint author]; Martini, Jean-Francois; Iiri, Taroh; Fantl, Wendy J.; Martial, Joseph; Weiner, Richard I.
 CS Institut de Pharmacologie Moleculaire et Cellulaire, UPR411 Centre Nationale de la Recherche Scientifique, Sophia-Antipolis, 06050, Valbonne, France
 SO Molecular Endocrinology, (May, 1999) Vol. 13, No. 5, pp. 692-704. print.
 CODEN: MOENEN. ISSN: 0888-8809.
 DT Article
 LA English
 ED Entered STN: 17 Aug 1999
 Last Updated on STN: 17 Aug 1999

=> d 7 ab

L5 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2004 ACS on STN
 AB A review. Endothelial cells are the key regulators of vascular tone, permeability, and neovascular growth. Because of the enormous biol. impact of these processes, the regulation of endothelial cell function represents a key therapeutic target in a wide array of diseases ranging from overt vascular diseases, such as hypertension and stroke, to tumor growth and metastases. As such, the focus of many labs. is the elucidation of the signal transduction pathways within endothelial cells which regulate their behavior. This has contributed to an enhanced understanding of endothelial cell biol. and to the discovery of novel therapeutics for diseases. Recently, particular attention has been paid to the processes regulating ***angiogenesis***, the sprouting of endothelial cells from a preexisting blood vessel in order to form a new vessel. This strategy has led to recent clin. successes with compds. such as Avastin, a monoclonal antibody that blocks vascular endothelial growth

factor (VEGF) signaling. Here we examine the results of recent studies from our lab. and others revealing a role for integrins and growth factors in regulating ***angiogenesis*** and how modulation of these mols. and their downstream signaling might be used therapeutically.

=> d 11-14

L5 ANSWER 11 OF 14 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 1998:694581 SCISEARCH
GA The Genuine Article (R) Number: 117JL
TI Protein kinase G mediates vascular endothelial growth factor-induced
Raf -1 activation and proliferation in ***human*** endothelial
cells
AU Hood J; Granger H J (Reprint)
CS TEXAS A&M UNIV SYST, HLTH SCI CTR, MICROCIRCULAT RES INST, COLLEGE STN, TX
77843 (Reprint); TEXAS A&M UNIV SYST, HLTH SCI CTR, MICROCIRCULAT RES
INST, COLLEGE STN, TX 77843; TEXAS A&M UNIV SYST, HLTH SCI CTR, DEPT MED
PHYSIOL, COLLEGE STN, TX 77843
CYA USA
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (4 SEP 1998) Vol. 273, No. 36, pp.
23504-23508.
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE
PIKE, BETHESDA, MD 20814.
ISSN: 0021-9258.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 45
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 12 OF 14 MEDLINE on STN DUPLICATE 3
AN 1999067717 MEDLINE
DN PubMed ID: 9850731
TI Inhibitory effect of theobromine on induction of ***angiogenesis***
and VEGF mRNA expression in v- ***raf*** transfectants of ***human***
urothelial cells HCV-29.
AU Skopinska-Rozewska E; Janik P; Przybyszewska M; Sommer E; Bialas-Chromiec
B
CS Department of Immunology, National Institute of Tuberculosis and Lung
Diseases, Warsaw, Poland.
SO International journal of molecular medicine, (1998 Dec) 2 (6) 649-52.
Journal code: 9810955. ISSN: 1107-3756.
CY Greece
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199901
ED Entered STN: 19990115
Last Updated on STN: 20000303
Entered Medline: 19990107

L5 ANSWER 13 OF 14 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:41864 BIOSIS
DN PREV199900041864
TI ***Angiogenesis*** induced by urothelial cells (HCV-29) and their
v-ras and v-raf transfectants.
AU Przybyszewska, Malgorzata; Miloszevska, Joanna; Janik, Przemyslaw [Reprint
author]
CS Dep. Cell Biol., Maria Skłodowska-Curie Cancer Cent., W.K. Roentgen Str.
5, 02-781 Warsaw, Poland
SO Cancer Letters, (Sept. 25, 1998) Vol. 131, No. 2, pp. 157-161. print.
CODEN: CALEDQ. ISSN: 0304-3835.
DT Article
LA English
ED Entered STN: 3 Feb 1999
Last Updated on STN: 3 Feb 1999

L5 ANSWER 14 OF 14 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1997-414636 [38] WPIDS
CR 1996-030518 [03]; 1997-043050 [04]; 1999-120502 [10]; 1999-527018 [44];
2000-531424 [48]; 2002-597918 [64]; 2003-503332 [47]; 2003-863446 [80]
DNC C1997-132718
TI Inhibition of ***human*** ***raf*** expression with anti sense
oligo nucleotide - especially for treating hyper proliferative diseases.
DC B04 D16

IN MONIA, B P
PA (ISIS-N) ISIS PHARM INC
CYC 1
PI US 5656612 A 19970812 (199738)* 12 A61K031-70
ADT US 5656612 A CIP of US 1994-250856 19940531, US 1995-460235 19950602
FDT US 5656612 A CIP of US 5563255
PRAI US 1995-460235 19950602; US 1994-250856 19940531
IC ICM A61K031-70
ICS C07H021-00; C12N015-85

=> dis his

(FILE 'HOME' ENTERED AT 19:16:48 ON 03 AUG 2004)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS,
NTIS, ESBIODBASE, BIOTECHNO, WPIDS' ENTERED AT 19:16:59 ON 03 AUG 2004
L1 35040 S RAF
L2 1672 S L1 (5A) HUMAN
L3 0 S L2 (5A) ANGIOGENESIS
L4 18 S L2 AND ANGIOGENESIS
L5 14 DUP REM L4 (4 DUPLICATES REMOVED)

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	41.01	41.22
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.74	-0.74

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 19:22:56 ON 03 AUG 2004